Cleveland Clinic Florida's Cancer Research staff is dedicated to providing patients innovative therapies through clinical research trials which include new targeted agents and therapies. Cancer specialists from The Maroone Cancer's Departments of Hematology and Oncology serve as principal investigators for the trials, working closely with the research staff and collaborating with the world-renowned Taussig Cancer Institute at Cleveland Clinic in Ohio. Cleveland Clinic Florida also participates in many clinical trials with the National Cancer Institute.

For more information about our clinical trials, please contact:
Abel Rodriguez, Clinical Research Supervisor
Phone: 954.487.2258
Email: RODRIGA2@ccf.org

Areas of Cancer Clinical Trials

Brain Cancer

No trials currently available.


Breast Cancer

NSABP B-51 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

SWOG S1416 - Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

A Phase IB/II Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-Dm1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer

A Randomized Phase III Trial Of Endocrine Therapy Plus Entinostat/Placebo In Patients With Hormone Receptor-Positive Advanced Breast Cancer

NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Molecular Mechanisms Involved in Cancer Predisposition

  • Cleveland Clinic Study Number: IRB 8458
  • Principal Investigator: Charis Eng, MD

Colorectal/Lung

A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

  • Trial Description
  • Sponsor Study Number:  NCI 10021 / DFCI 1Y17
  • Cleveland Clinic Study Number: IRB 18-014
  • Principal Investigator: Arun Nagarajan, MD / Bruno Bastos, MD

Gastrointestinal

Endoesophageal Brachytherapy for Patients with Esophageal Cancer: A Balloon Repositioning, Multichannel Radiation Applicator for Optimizing Treatment Delivery


Genitourinary

Please check back for upcoming trials.


Head & Neck Cancer

Please check back for upcoming trials.


Hematology

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

A Phase 3 Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults

A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma

Collection of Blood and Bone Marrow from Normal Volunteers and Patients for Research Purposes

  • Sponsor Study Number: 5024
  • Cleveland Clinic Study Number: IRB 5024
  • Principal Investigator: Chieh-Lin Fu, MD

Lung Cancer

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

MUSC 1516 / Prot# 102323 - A Phase IB/II Study of Nivolumab in Combination with ALT-803 in Patients with Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Adjuvant Lung Cancer Enrichment Market Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512

Randomized Double Blind Placebo Controlled Study of ERLOTINIB or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

A Phase III Double-Blind Trial for Surgically Resected Early State Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Randomized Phase III Study Of Nivolumab After Surgical Resection And Adjuvant Chemotherapy In Non-Small Cell Lung Cancers - Adjuvant Nivolumab In Resected Lung Cancers (Anvil)


Prostate Cancer

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial


Solid Tumor Cancer

No trials currently available.